177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

NCT04167618 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Business priorities

Conditions

Medulloblastoma, Childhood

Interventions

DRUG: 177Lu-DTPA-omburtamab

Sponsor

Y-mAbs Therapeutics